Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Key Statistical Concepts in Clinical Trials for Pharma (eBook)

(Autor)

eBook Download: PDF
2011 | 2012
IX, 61 Seiten
Springer New York (Verlag)
978-1-4614-1662-3 (ISBN)

Lese- und Medienproben

Key Statistical Concepts in Clinical Trials for Pharma - J. Rick Turner
Systemvoraussetzungen
53,49 inkl. MwSt
(CHF 52,25)
Der eBook-Verkauf erfolgt durch die Lehmanns Media GmbH (Berlin) zum Preis in Euro inkl. MwSt.
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.

J. Rick Turner, PhD, is an experimental research scientist and clinical trialist, and currently Senior Scientific Director, Integrated Cardiovascular Safety, Quintiles. With his colleagues, he provides Sponsors with consultation, strategic and regulatory insights, and operational support during cardiac safety assessments throughout clinical development programs.  He is particularly interested in the development of drugs for Type 2 Diabetes Mellitus and obesity.Dr Turner is also a Senior Fellow at the Center for Medicine in the Public Interest (New York) and Editor-in-Chief of the DIA's peer-reviewed Drug Information Journal.  He has published 12 previous books, 65 peer-reviewed papers, and many articles in professional journals. His books include:

·         Turner JR, 2011, A Concise Guide to Clinical Trials. Chapel Hill, NC: Turner Medical Communications LLC.

·         Turner JR, 2010, New Drug Development: An Introduction to Clinical Trials, 2nd Edition.  New York: Springer.

·         Turner JR, Durham TA, 2009, Integrated Cardiac Safety: Assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Hoboken, NJ: John Wiley & Sons.

·         Durham TA, Turner JR, 2008, Introduction to Statistics in Pharmaceutical Clinical Trials.  London: Pharmaceutical Press.

Dr Turner is also a Senior Fellow at the Center for Medicine in the Public Interest (New York) and Editor-in-Chief of the DIA's peer-reviewed Drug Information Journal.  He has published 12 previous books, 65 peer-reviewed papers, and many articles in professional journals. His books include:

·         Turner JR, 2011, A Concise Guide to Clinical Trials. Chapel Hill, NC: Turner Medical Communications LLC.

·         Turner JR, 2010, New Drug Development: An Introduction to Clinical Trials, 2nd Edition.  New York: Springer.

·         Turner JR, Durham TA, 2009, Integrated Cardiac Safety: Assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Hoboken, NJ: John Wiley & Sons.

·         Durham TA, Turner JR, 2008, Introduction to Statistics in Pharmaceutical Clinical Trials.  London: Pharmaceutical Press.


This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.

J. Rick Turner, PhD, is an experimental research scientist and clinical trialist, and currently Senior Scientific Director, Integrated Cardiovascular Safety, Quintiles. With his colleagues, he provides Sponsors with consultation, strategic and regulatory insights, and operational support during cardiac safety assessments throughout clinical development programs.  He is particularly interested in the development of drugs for Type 2 Diabetes Mellitus and obesity.Dr Turner is also a Senior Fellow at the Center for Medicine in the Public Interest (New York) and Editor-in-Chief of the DIA’s peer-reviewed Drug Information Journal.  He has published 12 previous books, 65 peer-reviewed papers, and many articles in professional journals. His books include:·         Turner JR, 2011, A Concise Guide to Clinical Trials. Chapel Hill, NC: Turner Medical Communications LLC.·         Turner JR, 2010, New Drug Development: An Introduction to Clinical Trials, 2nd Edition.  New York: Springer.·         Turner JR, Durham TA, 2009, Integrated Cardiac Safety: Assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Hoboken, NJ: John Wiley & Sons.·         Durham TA, Turner JR, 2008, Introduction to Statistics in Pharmaceutical Clinical Trials.  London: Pharmaceutical Press.Dr Turner is also a Senior Fellow at the Center for Medicine in the Public Interest (New York) and Editor-in-Chief of the DIA’s peer-reviewed Drug Information Journal.  He has published 12 previous books, 65 peer-reviewed papers, and many articles in professional journals. His books include:·         Turner JR, 2011, A Concise Guide to Clinical Trials. Chapel Hill, NC: Turner Medical Communications LLC.·         Turner JR, 2010, New Drug Development: An Introduction to Clinical Trials, 2nd Edition.  New York: Springer.·         Turner JR, Durham TA, 2009, Integrated Cardiac Safety: Assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Hoboken, NJ: John Wiley & Sons.·         Durham TA, Turner JR, 2008, Introduction to Statistics in Pharmaceutical Clinical Trials.  London: Pharmaceutical Press.

Setting the Scene.- Analyzing Safety Data.- Assessing Efficacy Data.- Confidence Intervals: Additional Commentary.- Meta-methodology.- Benefit-risk Estimation

Erscheint lt. Verlag 14.10.2011
Reihe/Serie SpringerBriefs in Pharmaceutical Science & Drug Development
SpringerBriefs in Pharmaceutical Science & Drug Development
Zusatzinfo IX, 61 p. 1 illus.
Verlagsort New York
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Studium
Technik
Schlagworte Clinical Trials • Pharma • Statistical Concepts • Statistics
ISBN-10 1-4614-1662-0 / 1461416620
ISBN-13 978-1-4614-1662-3 / 9781461416623
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 2,0 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich